Skip to main content
. 2020 Aug;16(3):202–211. doi: 10.2174/1573403X14666180702151626

Table 2.

Some pathways under investigation for new HF drugs.

Apelin
Interleukin-1b receptor antagonists
Atrial natriuretic peptides
Mineralocorticoid receptor antagonists
β3 agonists
Mitochondrial targeting peptide
Neuregulin-1
Cardiac ion channels modulator